A phase II trial of second-line irinotecan and capecitabine after failure of first line infusional 5-fluorouracil and folinic acid in metastatic colorectal cancer (MCRC)

Folinic Acid ◽

Phase Ii ◽

Phase Ii Trial ◽

Second Line ◽

First Line

A phase II trial of second-line irinotecan and capecitabine after failure of first line infusional 5-fluorouracil and folinic acid in metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3752 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3752-3752

Author(s):

A. M. Willer ◽

R. D. Hofheinz ◽

A. Wein ◽

U. Gnad-Vogt ◽

S. Saussele ◽

...

Keyword(s):

Colorectal Cancer ◽

Folinic Acid ◽

Phase Ii ◽

Phase Ii Trial ◽

Second Line ◽

First Line

Palliative first-line treatment with weekly high-dose 5-fluorouracil (5-FU) and sodium folinic acid (s-FA) (AIO-schedule) as 24h-infusion plus biweekly oxaliplatin (ox) in patients with definitively nonresectable metastatic colorectal cancer (CRC) following secondary (sec) metastatic resection: An interdisciplinary phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.15064 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 15064-15064

Author(s):

H. Albrecht ◽

A. Wein ◽

K. Wolff ◽

V. Brueckl ◽

C. Meier ◽

...

Keyword(s):

Colorectal Cancer ◽

Folinic Acid ◽

Phase Ii ◽

Phase Ii Trial ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Palliative first-line treatment with weekly high-dose 5-fluorouracil and sodium folinic acid (s-FA) (AIO-schedule) as 24h-infusion plus bi-weekly oxaliplatin (ox) in patients with definitively non-resectable metastatic colorectal cancer (CRC) following secondary (s.) metastatic resection: An interdisciplinary phase II-Trial

Zeitschrift für Gastroenterologie ◽

10.1055/s-0028-1089593 ◽

2008 ◽

Vol 46 (09) ◽

Author(s):

H Albrecht ◽

A Wein ◽

C Meier ◽

N Ostermeier ◽

V Brueckl ◽

...

Keyword(s):

Colorectal Cancer ◽

Folinic Acid ◽

Phase Ii ◽

Phase Ii Trial ◽

High Dose ◽

Line Treatment ◽

First Line ◽

A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), “Mayo regimen”, in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC)

European Journal of Cancer ◽

10.1016/s0959-8049(99)80646-7 ◽

1999 ◽

Vol 35 ◽

pp. S70 ◽

Cited By ~ 6

Author(s):

C. Pozzo ◽

S. Pyrhönen ◽

I. Bodrogi ◽

J. Szanto ◽

H. Kamica-Mlodkowska ◽

...

Keyword(s):

Colorectal Cancer ◽

Folinic Acid ◽

Phase Ii ◽

Palliative Chemotherapy ◽

Phase Ii Trial ◽

First Line ◽

Randomized Phase Ii ◽

Chemotherapy Patients

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

British Journal of Cancer ◽

10.1038/bjc.2011.594 ◽

2012 ◽

Vol 106 (3) ◽

pp. 453-459 ◽

Cited By ~ 37

Author(s):

J Souglakos ◽

N Ziras ◽

S Kakolyris ◽

I Boukovinas ◽

N Kentepozidis ◽

...

Keyword(s):

Colorectal Cancer ◽

Unresectable Metastatic Colorectal Cancer

Folinic Acid ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

First Line Treatment ◽

416P Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.937 ◽

2021 ◽

Vol 32 ◽

pp. S543

Author(s):

J. Aparicio ◽

A.C. Virgili Manrique ◽

J. Capdevila ◽

F. Muñoz Boza ◽

P. Galván ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Second Line ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of Oncology ◽

10.1016/s0923-7534(21)00330-6 ◽

2016 ◽

Vol 27 ◽

pp. ix54

Author(s):

T. Ando ◽

S. Yuki ◽

H. Nakatsumi ◽

T. Muranaka ◽

A. Hosokawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Analysis Phase ◽

Administration Interval

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Cited By ~ 1

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽